Association between Helicobacter pylori infection and Guillain-Barré Syndrome: A meta-analysis
Corresponding Author
Efthimios Dardiotis
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Correspondence
Dardiotis Efthimios, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, Biopolis, Mezourlo Hill, Larissa 41100, Greece.
Email: [email protected]
Search for more papers by this authorMaria Sokratous
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorZisis Tsouris
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorVasileios Siokas
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorAlexios-Fotios A. Mentis
Department of Microbiology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Public Health Laboratories, Hellenic Pasteur Institute, Athens, Greece
Search for more papers by this authorAthina-Maria Aloizou
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorAmalia Michalopoulou
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorDimitrios P. Bogdanos
Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Cellular Immunotherapy & Molecular Immunodiagnostics, Biomedical Section, Centre for Research and Technology-Hellas (CERTH)-Institute for Research and Technology-Thessaly (IRETETH), Larissa, Greece
Search for more papers by this authorGeorgia Xiromerisiou
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorGeorgia Deretzi
Department of Neurology, Papageorgiou General Hospital, Thessaloniki, Greece
Search for more papers by this authorJannis Kountouras
Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece
Search for more papers by this authorGeorgios M. Hadjigeorgiou
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus
Search for more papers by this authorCorresponding Author
Efthimios Dardiotis
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Correspondence
Dardiotis Efthimios, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, Biopolis, Mezourlo Hill, Larissa 41100, Greece.
Email: [email protected]
Search for more papers by this authorMaria Sokratous
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorZisis Tsouris
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorVasileios Siokas
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorAlexios-Fotios A. Mentis
Department of Microbiology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Public Health Laboratories, Hellenic Pasteur Institute, Athens, Greece
Search for more papers by this authorAthina-Maria Aloizou
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorAmalia Michalopoulou
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorDimitrios P. Bogdanos
Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Cellular Immunotherapy & Molecular Immunodiagnostics, Biomedical Section, Centre for Research and Technology-Hellas (CERTH)-Institute for Research and Technology-Thessaly (IRETETH), Larissa, Greece
Search for more papers by this authorGeorgia Xiromerisiou
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Search for more papers by this authorGeorgia Deretzi
Department of Neurology, Papageorgiou General Hospital, Thessaloniki, Greece
Search for more papers by this authorJannis Kountouras
Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece
Search for more papers by this authorGeorgios M. Hadjigeorgiou
Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece
Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus
Search for more papers by this authorAbstract
Background
Helicobacter pylori (H pylori) is a Gram-negative bacterium, considered to trigger autoimmune gastrointestinal disorders. This pathogen has also been linked to the autoimmune sequelae in extra-gastrointestinal diseases and peripheral neuropathies. Guillain-Barré syndrome (GBS) is a serious autoimmune demyelinating disorder of peripheral nerves, usually with a post-infectious onset. About 30% of cases of GBS attributed to by Campylobacter jejuni, so, H pylori, could be also involved. Growing evidence suggests the likely involvement of H pylori infection in the development of GBS. The aim of the current study was to therefore estimate the prevalence of H pylori antibodies in GBS.
Methods
A search of the literature was performed, using the PUBMED database, until December 2018. Data were extracted from six case-control studies, and a stratification analysis was conducted according to cerebrospinal fluid (CSF) or serum detection material.
Results
Among 29 records found, 6 studies met in the inclusion criteria for the meta-analysis. In the CSF subgroup, 105 participants were involved (40 GBS patients and 65 controls), while the serum subgroup included 325 participants (152 GBS and 173 controls). Data were combined using a fixed-effects model. Anti-H pylori IgG were significantly more prevalent in GBS patients compared to controls, in both CSF (95% CI: 9.66-186.56, OR: 42.45, Pz < .00001) and serum (95% CI: 1.30-4.11, OR: 2.31, Pz: .004) subgroups.
Conclusion
The present meta-analysis showed a strong association between GBS and the presence of H pylori antibodies, especially in CSF, thereby suggesting a role of H pylori infection in the pathophysiology of GBS.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.
Supporting Information
| Filename | Description |
|---|---|
| eci13218-sup-0001-FileS1.docWord document, 15 KB | FileS1 |
| eci13218-sup-0002-FileS2.docWord document, 63 KB | FileS2 |
| eci13218-sup-0003-FigureS1.tifTIFF image, 54.3 KB | FigureS1 |
| eci13218-sup-0004-FigureS2.tifTIFF image, 56.1 KB | FigureS2 |
| eci13218-sup-0005-legends.docxWord document, 13.7 KB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Amieva M, Peek RM Jr. Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroenterology. 2016; 150(1): 64-78.
- 2Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biomed J. 2016; 39(1): 14-23.
- 3Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014; 19(Suppl 1): 1-5.
- 4Mentis AA, Boziki M, Grigoriadis N, Papavassiliou AG. Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cell Mol Life Sci. 2019; 76(13): 2477-2486.
- 5Mentis AA, Dardiotis E. Helicobacter pylori Eradication for metachronous gastric cancer: an unsuitable methodology impeding broader clinical usage. Front Oncol. 2019; 9: 90.
- 6Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause or bystander. World J Gastroenterol. 2014; 20(3): 613-629.
- 7Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter. 2015; 20(Suppl 1): 40-46.
- 8Astl J, Sterzl I. Activation of Helicobacter pylori causes either autoimmune thyroid diseases or carcinogenesis in the digestive tract. Physiol Res. 2015; 64(Suppl 2): S291-S301.
- 9Deretzi G, Gavalas E, Boziki M, et al. Impact of Helicobacter pylori on multiple sclerosis-related clinically isolated syndrome. Acta Neurolo Scand. 2016; 133(4): 268-275.
- 10Choi YM, Kim TY, Kim EY, et al. Association between thyroid autoimmunity and Helicobacter pylori infection. Korean J Intern Med. 2017; 32(2): 309-313.
- 11Dardiotis E, Tsouris Z, Mentis AA, et al. H. pylori and Parkinson’s disease: meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018; 175: 16-24.
- 12Kountouras J, Zavos C, Chatzopoulos D. Apoptosis and autoimmunity as proposed pathogenetic links between Helicobacter pylori infection and idiopathic achalasia. Med Hypotheses. 2004; 63(4): 624-629.
- 13Chiba S, Sugiyama T, Yonekura K, et al. An antibody to VacA of Helicobacter pylori in the CSF of patients with Miller-Fisher syndrome. Neurology. 2004; 63(11): 2184-2186.
- 14van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014; 10(8): 469-482.
- 15Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 388(10045), 717-727.
- 16Dimachkie MM, Barohn RJ. Guillain-Barré Syndrome and Variants. Neurol Clin. 2013; 31(2): 491-510.
- 17Zautner AE, Johann C, Strubel A, et al. Seroprevalence of campylobacteriosis and relevant post-infectious sequelae. Eur J Clin Microbiol Infect Dis. 2014; 33(6): 1019-1027.
- 18Tolunay O, Çelik T, Çelik Ü, Kömür M, Tanyeli Z, Sönmezler A. Concurrency of Guillain-Barre syndrome and acute transverse myelitis: a case report and review of literature. Korean J Pediatr. 2016; 59(Suppl 1): S161-S164.
- 19Esposito S, Longo MR. Guillain-Barre syndrome. Autoimmun Rev. 2017; 16(1): 96-101.
- 20Krauer F, Riesen M, Reveiz L, et al. Zika Virus infection as a cause of congenital brain abnormalities and Guillain-Barre syndrome: systematic review. PLoS Med. 2017; 14(1):e1002203.
- 21Annunziata P, Figura N, Galli R, Mugnaini F, Lenzi C. Association of anti-GM1 antibodies but not of anti-cytomegalovirus, Campylobacter jejuni and Helicobacter pylori IgG, with a poor outcome in Guillain-Barre syndrome. J Neurol Sci. 2003; 213(1–2): 55-60.
- 22Goodfellow JA, Willison HJ. Guillain-Barre syndrome: a century of progress. Nat Rev Neurol. 2016; 12(12): 723-731.
- 23Álvarez-Arellano L, Maldonado-Bernal C Helicobacter pylori and neurological diseases: married by the laws of inflammation. World J Gastrointest Pathophysiol. 2014; 5(4): 400-404.
- 24Chiba S, Sugiyama T, Matsumoto H, et al. Antibodies against Helicobacter pylori were detected in the cerebrospinal fluid obtained from patients with Guillain-Barre syndrome. Ann Neurol. 1998; 44(4): 686-688.
- 25Chiba S, Sugiyama T, Yonekura K, et al. An antibody to VacA of Helicobacter pylori in cerebrospinal fluid from patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2002; 73(1): 76-78.
- 26Kountouras J, Deretzi G, Zavos C, et al. Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2005; 12(2): 139-143.
- 27Ghabaee M, Ghanbarian D, Brujeni GN, Bokaei S, Siavoshi F, Gharibzadeh S. Could Helicobacter pylori play an important role in axonal type of Guillain-Barre syndrome pathogenesis? Clin Neurol Neurosurg. 2010; 112(3): 193-198.
- 28DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-188.
- 29Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4): 719-748.
- 30Siokas V, Dardiotis E, Tsironi EE, et al. The role of TOR1A polymorphisms in dystonia: a systematic review and meta-analysis. PloS One. 2017; 12(1):e0169934.
- 31Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700.
- 32Moran AP, Prendergast MM. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J Autoimmun. 2001; 16(3): 241-256.
- 33Moran AP. The role of endotoxin in infection: Helicobacter pylori and Campylobacter jejuni. Sub-cell Biochem. 2010; 53: 209-240.
- 34Zhang M, Gilbert M, Yuki N, et al. Association of Anti-GT1a antibodies with an outbreak of Guillain-Barre syndrome and analysis of ganglioside mimicry in an associated Campylobacter jejuni strain. PloS One. 2015; 10(7):e0131730.
- 35Li H, Liao T, Debowski AW, et al. Lipopolysaccharide structure and biosynthesis in Helicobacter pylori. Helicobacter. 2016; 21(6): 445-461.
- 36Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem. 1992; 267(15): 10570-10575.
- 37Kountouras J, Zavos C, Deretzi G, et al. Potential implications of Helicobacter pylori-related neutrophil-activating protein. World J Gastroenterol. 2012; 18(5): 489-490.
- 38Lilje O, Armati PJ. Restimulation of resting autoreactive T cells by Schwann cells in vitro. Exp Mol Pathol. 1999; 67(3): 164-174.
- 39Kountouras J, Deretzi G, Zavos C, et al. Helicobacter pylori infection may trigger Guillain-Barre syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis. J Neurol Sci. 2011; 305(1–2): 167-168; author reply 169.
- 40Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Exs. 1997; 79: 233-269.
- 41Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010; 20(2): 87-103.
- 42Gonzalez-Quevedo A, Carriera RF, O'Farrill ZL, Luis IS, Becquer RM, Luis Gonzalez RS. An appraisal of blood-cerebrospinal fluid barrier dysfunction during the course of Guillain Barre syndrome. Neurol India. 2009; 57(3): 288-294.
- 43Yuki N, Shahrizaila N. How do we identify infectious agents that trigger Guillain-Barre syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis? J Neurol Sci. 2011; 302(1–2): 1-5.
- 44Kountouras J, Deretzi G, Grigoriadis N, et al. Guillain-Barre syndrome. Lancet Neurol. 2008; 7(12): 1080-1081; author reply 1083–1085.
- 45Kountouras J, Zavos C, Deretzi G, et al. Helicobacter pylori may play an important role in both axonal type Guillain-Barre syndrome and acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurol Neurosurg. 2011; 113(6): 520.
- 46Kienesberger S, Cox LM, Livanos A, et al. Gastric Helicobacter pylori infection affects local and distant microbial populations and host responses. Cell Rep. 2016; 14(6): 1395-1407.
- 47Klymiuk I, Bilgilier C, Stadlmann A, et al. The human gastric microbiome is predicated upon infection with Helicobacter pylori. Front Microbiol. 2017; 8: 2508.
- 48Noto JM, Peek RM Jr. The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS Pathog. 2017; 13(10):e1006573.
- 49Bravo D, Hoare A, Soto C, Valenzuela MA, Quest AF. Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018; 24(28): 3071-3089.
- 50Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 2011; 5(4): 574-579.
- 51Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018; 67(9): 1716-1725.
- 52Hillman ET, Lu H, Yao T, Nakatsu CH. Microbial ecology along the gastrointestinal tract. Microbes Environ. 2017; 32(4): 300-313.
- 53Kho ZY, Lal SK. The human gut microbiome - a potential controller of wellness and disease. Front Microbiol. 2018; 9: 1835.
- 54Roubaud-Baudron C, Megraud F, Salles N, Dartigues JF, Letenneur L. Detecting both current and prior Helicobacter pylori infection is important to assess its impact on dementia. Alzheimer's Dement. 2019; 15(5): 721-722.
